Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $84.23.
Several research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Zillow Group from a “hold” rating to a “buy” rating in a report on Thursday. TheStreet downgraded shares of Twin Disc from a “b-” rating to a “c+” rating in a report on Tuesday, June 11th. Piper Jaffray Companies boosted their price objective on shares of Beigene to $180.00 and gave the stock an “overweight” rating in a report on Thursday, May 9th. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Finally, BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday.
TRHC traded up $0.56 during trading on Friday, hitting $54.59. The stock had a trading volume of 7,735 shares, compared to its average volume of 373,508. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 160.88 and a beta of 1.62. Tabula Rasa HealthCare has a 12 month low of $40.86 and a 12 month high of $91.16. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. The company has a 50 day simple moving average of $47.80.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). The firm had revenue of $60.96 million for the quarter, compared to the consensus estimate of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. As a group, research analysts forecast that Tabula Rasa HealthCare will post -0.55 EPS for the current year.
In other news, Director Gordon Tunstall sold 1,000 shares of Tabula Rasa HealthCare stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $51.52, for a total transaction of $51,520.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $48.50, for a total transaction of $388,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,270 shares of company stock worth $2,457,654. 11.80% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the company. First Mercantile Trust Co. boosted its position in Tabula Rasa HealthCare by 64.5% in the first quarter. First Mercantile Trust Co. now owns 995 shares of the company’s stock valued at $56,000 after buying an additional 390 shares in the last quarter. South Dakota Investment Council acquired a new position in Tabula Rasa HealthCare in the first quarter valued at about $141,000. Belpointe Asset Management LLC acquired a new position in Tabula Rasa HealthCare in the first quarter valued at about $172,000. LS Investment Advisors LLC boosted its position in Tabula Rasa HealthCare by 11.2% in the first quarter. LS Investment Advisors LLC now owns 3,129 shares of the company’s stock valued at $177,000 after buying an additional 316 shares in the last quarter. Finally, RMB Capital Management LLC acquired a new position in Tabula Rasa HealthCare in the fourth quarter valued at about $220,000. Institutional investors and hedge funds own 86.68% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
See Also: Bond
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.